PARD Related Analyst Ratings

Nov 18, 2009 09:12 AM Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward

Nov 18, 2009 08:26 AM Canaccord Adams Downgrades Poniard Pharmaceuticals (PARD) to Hold

Nov 17, 2009 09:11 AM Wedbush Downgrades Poniard Pharmaceuticals (PARD) to Underperform; Picoplatin SPEAR Phase III Study Fails

Nov 17, 2009 08:18 AM Rodman & Renshaw Downgrades Poniard Pharmaceuticals (PARD) to Market Perform

Nov 16, 2009 01:05 PM Needham & Co Downgrades Poniard Pharmaceuticals (PARD) to Hold on Phase 3 SPEAR Trial Results

Nov 16, 2009 11:40 AM Oppenheimer, BMO, Merriman, Needham Downgrade Poinard (PARD) Following Negative Picoplatin Data

Nov 16, 2009 09:31 AM Merriman Curhan Ford Downgrades Poniard Pharmaceuticals (PARD) to Neutral After Disappointing Phase III SPEAR Trial Results

Oct 6, 2009 08:09 AM BMO Capital Initiates Coverage on Poniard Pharmaceuticals (PARD) with a Speculative Outperform

Aug 5, 2009 11:34 AM Lazard Capital Downgrades Poniard Pharmaceuticals (PARD) to Hold

Jul 23, 2009 10:01 AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)

Jul 2, 2009 08:23 AM Brean Murray Starts Poniard Pharmaceuticals (PARD) with a Buy

Jun 5, 2009 03:51 PM Wedbush Morgan Maintains a 'Buy' on Poniard Pharmaceuticals (PARD); Renewed Interest in Emerging Pharma Sector - Raises Price Target

Mar 18, 2009 09:22 AM Needham & Co Initiates Coverage on Poniard Pharmaceuticals (PARD) with a Buy

Feb 10, 2009 10:59 AM Canaccord Adams Initiates Coverage on Several Life Sciences Stocks: ALTH, EXEL, MITI, NPSP, OSIP, ONXX, PARD, SGEN & SNTA

Oct 3, 2007 07:48 AM Credit Suisse Starts Poniard Pharmaceuticals (PARD) at Outperform

Jun 21, 2007 08:14 AM Oppenheimer Starts Poniard Pharma (PARD) at Buy

May 7, 2007 08:42 AM CIBC Starts Poniard Pharmaceuticals (PARD) at Sector Outperform